Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients
Arguably, no drug class has more radically and rapidly altered the management of non-small-cell lung cancer (NSCLC) than inhibitors of the interaction between programmed death 1 (PD-1) and its ligand PD-L1. By impeding this negative regulatory signal for T-cell response, PD-1 and PD-L1 inhibitors result in longer survival than does chemotherapy among patients with previously treated NSCLC.1-4 In this issue of the Journal, Carbone and colleagues report on a trial that compared the PD-1 inhibitor nivolumab with chemotherapy as first-line treatment for advanced NSCLC in a population of patients selected on the basis of PD-L1 expression level.5.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:376 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 376(2017), 25, Seite 2483 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Edward B Garon [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Cancer |
| RVK: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1995100897 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995100897 | ||
| 003 | DE-627 | ||
| 005 | 20230519014416.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1995100897 | ||
| 035 | |a (DE-599)GBVOLC1995100897 | ||
| 035 | |a (PRQ)p643-87faefa96ddb0413b9f6923d2841ab9a4325fd658314d0870343ff178d7569ae0 | ||
| 035 | |a (KEY)0171808820170000376002502483cancerimmunotherapytrialsnotimmunefromimprecisesel | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-101 |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 0 | |a Edward B Garon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Arguably, no drug class has more radically and rapidly altered the management of non-small-cell lung cancer (NSCLC) than inhibitors of the interaction between programmed death 1 (PD-1) and its ligand PD-L1. By impeding this negative regulatory signal for T-cell response, PD-1 and PD-L1 inhibitors result in longer survival than does chemotherapy among patients with previously treated NSCLC.1-4 In this issue of the Journal, Carbone and colleagues report on a trial that compared the PD-1 inhibitor nivolumab with chemotherapy as first-line treatment for advanced NSCLC in a population of patients selected on the basis of PD-L1 expression level.5 | ||
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Human subjects | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Inhibitor drugs | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Lung cancer | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 376(2017), 25, Seite 2483 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:376 |g year:2017 |g number:25 |g pages:2483 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1912254226 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 376 |j 2017 |e 25 |h 2483 | ||